Literature DB >> 25248006

Naive T cells in the gut of newly diagnosed, untreated adult patients with inflammatory bowel disease.

Carmen S Horjus Talabur Horje1, Sabine Middendorp, Elly van Koolwijk, Lian Roovers, Marcel J M Groenen, Peter J Wahab, Ellen G van Lochem.   

Abstract

BACKGROUND: The phenotype of the T-cell subpopulations and their related cytokine networks in the gastrointestinal mucosa of patients with inflammatory bowel disease can potentially be used as a predictive value for clinical course and response to therapy. Here, we analyzed T-cell subpopulations in newly diagnosed, untreated adult patients and correlated them with clinical presentation.
METHODS: Mucosal biopsies from duodenum, ileum, and colon mucosa of patients with Crohn's disease and ulcerative colitis and controls were obtained. The simple endoscopy score in Crohn's disease and the full Mayo score in ulcerative colitis were used to score disease activity. Mucosa-infiltrating T cells were characterized by flow cytometric immunophenotyping and were stimulated to assess cytokine secretion.
RESULTS: Based on the expression of the maturation and activation markers CD45RA and CD27, we identified 4 different profiles. Profile A contained mainly CD45RA+CD27+ naive T cells; profile B contained mainly CD45RA+CD27+ central memory T cells; profile C contained mainly CD45RA-CD27- effector memory T cells; and profile D consisted of similar percentages of these aforementioned subpopulations. Profile A was only observed in the ileum/colon of patients with inflammatory bowel disease, associated with upper gastrointestinal location and perianal disease in Crohn's disease and expressed more tumor necrosis factor α and less interferon γ. In contrast, profile D was restricted to controls. There was no correlation between the different T-cell profiles and endoscopic disease activity.
CONCLUSIONS: Newly diagnosed patients with inflammatory bowel disease display different T-cell maturation profiles in the gut mucosa, corresponding to distinct cytokine responses. Follow-up studies are needed to determine whether the profiles associate with clinical course and response to therapy.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25248006     DOI: 10.1097/MIB.0000000000000203

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  8 in total

1.  High endothelial venules associated with T cell subsets in the inflamed gut of newly diagnosed inflammatory bowel disease patients.

Authors:  C S Horjus Talabur Horje; C Smids; J W R Meijer; M J Groenen; M K Rijnders; E G van Lochem; P J Wahab
Journal:  Clin Exp Immunol       Date:  2017-01-31       Impact factor: 4.330

2.  Circulating integrin alpha4/beta7+ lymphocytes targeted by vedolizumab have a pro-inflammatory phenotype.

Authors:  James D Lord; S Alice Long; Donna M Shows; Jerill Thorpe; Katherine Schwedhelm; Janice Chen; Mariko Kita; Jane H Buckner
Journal:  Clin Immunol       Date:  2018-05-26       Impact factor: 3.969

Review 3.  Exploring the Early Phase of Crohn's Disease.

Authors:  Giorgos Bamias; Fabio Cominelli
Journal:  Clin Gastroenterol Hepatol       Date:  2020-09-16       Impact factor: 13.576

4.  AlphaE Integrin Expression Is Increased in the Ileum Relative to the Colon and Unaffected by Inflammation.

Authors:  Ryan Ichikawa; Christopher A Lamb; Jeff Eastham-Anderson; Alexis Scherl; Laura Raffals; William A Faubion; Miriam R Bennett; Anna K Long; John C Mansfield; John A Kirby; Mary E Keir
Journal:  J Crohns Colitis       Date:  2018-11-09       Impact factor: 9.071

5.  Enriched CD45RA-CD62L+ central memory T and decreased CD3+CD56+ natural killer T lymphocyte subsets in the rectum of ulcerative colitis patients.

Authors:  Masaya Iwamuro; Takahide Takahashi; Natsuki Watanabe; Takehiro Tanaka; Toshihiro Inokuchi; Sakiko Hiraoka; Fumio Otsuka; Hiroyuki Okada
Journal:  Int J Immunopathol Pharmacol       Date:  2022 Jan-Dec       Impact factor: 3.219

6.  Clinical value of the expression levels of protein tyrosine phosphatase non-receptor type 22.6 mRNA in peripheral blood mononuclear cells in Crohn's disease.

Authors:  Mei Hu; Zhitao Chen; Yusheng Liao; Jie Wu; Dan Zheng; Heng Zhang
Journal:  Clin Exp Immunol       Date:  2022-09-29       Impact factor: 5.732

7.  Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis.

Authors:  Britt Roosenboom; Ellen G van Lochem; Jos Meijer; Carolijn Smids; Stefan Nierkens; Eelco C Brand; Liselot W van Erp; Larissa G J M Kemperman; Marcel J M Groenen; Carmen S Horjus Talabur Horje; Peter J Wahab
Journal:  Cells       Date:  2020-04-06       Impact factor: 6.600

8.  The Importance of Molecular Immune Investigation in Therapeutic Clinical Development for Biomarker Assessment.

Authors:  Christopher A Lamb; John C Mansfield; John A Kirby; Mary E Keir
Journal:  J Crohns Colitis       Date:  2019-07-25       Impact factor: 9.071

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.